

UnitedHealthcare® Medicare Advantage Reimbursement Policy CMS 1500 UB04 Policy Number 2025R8207A

Autoimmune Rheumatic Disease Policy, Professional and Facility

IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY

This policy is applicable to UnitedHealthcare Medicare Advantage Plans offered by UnitedHealthcare and its affiliates.

You are responsible for submission of accurate claims. This reimbursement policy is intended to ensure that you are reimbursed based on the code or codes that correctly describe the health care services provided. UnitedHealthcare Medicare Advantage reimbursement policies use Current Procedural Terminology (CPT®*), Centers for Medicare and Medicaid Services (CMS), or other coding guidelines. References to CPT or other sources are for definitional purposes only and do not imply any right to reimbursement.

This reimbursement policy applies to all health care services billed on UB04 forms (CMS 1450) and to those billed on CMS 1500 forms. Coding methodology, industry-standard reimbursement logic, regulatory requirements, benefits design and other factors are considered in developing reimbursement policy.

This information is intended to serve only as a general resource regarding UnitedHealthcare's Medicare Advantage reimbursement policy for the services described and is not intended to address every aspect of a reimbursement situation. Accordingly, UnitedHealthcare Medicare Advantage may use reasonable discretion in interpreting and applying this policy to health care services provided in a particular case. Further, the policy does not address all issues related to reimbursement for health care services provided to UnitedHealthcare Medicare Advantage enrollees. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to: legislative mandates, the facility or other provider contracts, the enrollee's benefit coverage documents**, and/or other reimbursement, medical or drug policies. Finally, this policy may not be implemented exactly the same way on the different electronic claims processing systems used by UnitedHealthcare Medicare Advantage due to programming or other constraints; however, UnitedHealthcare Medicare Advantage strives to minimize these variations.

UnitedHealthcare Medicare Advantage may modify this reimbursement policy at any time to comply with changes in CMS policy and other national standard coding guidelines by publishing a new version of the reimbursement policy on this website. However, the information presented in this reimbursement policy is accurate and current as of the date of publication. UnitedHealthcare Medicare Advantage encourages physicians and other health care professionals to keep current with any CMS policy changes and/or billing requirements by referring to the CMS or your local carrier website regularly. Facilities can sign up for regular distributions for policy or regulatory changes directly from CMS and/or your local carrier. UnitedHealthcare's Medicare Advantage reimbursement policies do not include notations regarding prior authorization requirements.

*CPT Copyright American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

** For more information on a specific enrollee's benefit coverage, please call the customer service number on the back of the member ID card.

Table of Contents

Application

Policy

Overview

Reimbursement Guidelines

Antinuclear Antibodies and Extractable Nuclear Antigen

Cell-Bound Complement Activation

Diagnostic Testing

Questions and Answers

Resources

History



UnitedHealthcare® Medicare Advantage
Reimbursement Policy
CMS 1500
UB04
Policy Number 2025R8207A

Application

This reimbursement policy applies to all Medicare Advantage products and for network provider services reported using the UB04 and CMS 1500 form or its electronic equivalent or its successor form.

Policy

Overview

This policy describes the reimbursement methodology for biomarker testing associated with autoimmune rheumatic disease.

Reimbursement Guidelines

NOTE: Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Antinuclear Antibodies and Extractable Nuclear Antigen

UnitedHealthcare will not consider reimbursement of antinuclear antibodies (ANA) and extractable nuclear antigen (ENA) testing procedure codes for a general encounter without abnormal findings or if submitted in conjunction with a preventive procedure code listed below per date of service:

Procedure Code(s)

<u> 10000aa10 00a0(0</u>				
86038	86039	86235		

Preventive Procedure Code(s)

	u. c				
99429	99411	99412	99401	99402	99403
99404	99381	99382	99383	99384	99385
99386	99387	99391	99392	99393	99394
99395	99396	99397			

Cell-Bound Complement Activation

UnitedHealthcare will not consider reimbursement of the following procedure code for the use of cell-bound complement activation products (e.g., Avise Lupus).

Pro	cedure	Code	(2)

0312U			

Diagnostic Testing

UnitedHealthcare will not consider reimbursement of serum biomarker panel testing with proprietary algorithms and index scores for the diagnosis of systemic lupus erythematosus or connective tissue diseases when submitted for the conditions of systemic lupus erythematosus or connective tissue disease.

Procedure Code(s)

00620 04460 04470		0062U	0446U	0447U			
-------------------	--	-------	-------	-------	--	--	--



UnitedHealthcare® Medicare Advantage Reimbursement Policy CMS 1500 UB04 Policy Number 2025R8207A

Questions and Answers

Q: Is the per date of service criteria based on individual provider per member?

A: The per date of service criteria is regardless of billing and/or rendering provider (any individual provider OR any facility) for each individual member for the same date of service.

Resources

1

American Medical Association (AMA) Current Procedural Terminology (CPT®)

Centers for Medicare and Medicaid Services: PFS Relative Value Files

History

12/1/2025	New Policy